title: Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS.
abstract: A sensitive liquid chromatography coupled with tandem mass spectrometry (MS/MS) method for the analysis in a small volume of plasma of 14 tyrosine kinase inhibitors currently used (imatinib, dasatinib, ibrutinib, ponatinib, trametinib, sunitinib, cobimetinib, dabrafenib, erlotinib, lapatinib, nilotinib, bosutinib, sorafenib, and vemurafenib) has been developed and validated. This multianalyte liquid chromatography coupled with MS/MS assay is of interest for anticancer drug combination therapy.
  
  
  
  After a simple protein precipitation of plasma samples, the chromatographic separation was performed using an ultra performance liquid chromatography system coupled with MS/MS in a positive ionization mode. The mobile phase consisted of a gradient elution of 10 mmol/L formate ammonium buffer containing 0.1% (vol/vol) formic acid (phase A) and acetonitrile with 0.1% (vol/vol) formic acid (phase B) at a flow rate of 300 μL/min.
  
  
  
  The analysis time was 5.0 minutes per run, and all analytes and internal standard eluted within 1.45-1.79 minutes. The calibration curves were linear over the range from 1 to 500 ng/mL for bosutinib, cobimetinib, dasatinib, ibrutinib, and trametinib, from 5 to 500 ng/mL for ponatinib and sunitinib; from 50 to 2500 ng/mL for lapatinib; from 750 to 100,000 ng/mL for vemurafenib, and from 10 to 2500 ng/mL for dabrafenib, erlotinib, imatinib, nilotinib, and sorafenib, with coefficients of correlation above 0.99 for all analytes. The intra- and interday imprecisions were below 14.36%.
  
  
  
  This method was successfully applied to therapeutic drug monitoring in clinical practice.
authors.affiliation: Departments of *Pharmacology and †Pharmacy, AP-HP, Hôpital Saint-Louis; ‡INSERM UMR_S976, Université Paris-Diderot, Sorbonne Paris Cité; and Departments of §Dermatology and ¶Hematology, AP-HP, Hôpital Saint-Louis, Paris, France.
authors.forename: Huu H
authors.initials: HH
authors.lastname: Huynh
authors.forename: Claire
authors.initials: C
authors.lastname: Pressiat
authors.forename: Hélène
authors.initials: H
authors.lastname: Sauvageon
authors.forename: Isabelle
authors.initials: I
authors.lastname: Madelaine
authors.forename: Patricia
authors.initials: P
authors.lastname: Maslanka
authors.forename: Céleste
authors.initials: C
authors.lastname: Lebbé
authors.forename: Catherine
authors.initials: C
authors.lastname: Thieblemont
authors.forename: Lauriane
authors.initials: L
authors.lastname: Goldwirt
authors.forename: Samia
authors.initials: S
authors.lastname: Mourah
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000097:blood*; D015203:Reproducibility of Results; D053719:Tandem Mass Spectrometry / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors